Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACT in CAKUT CKD
NCT04115345Phase 1Completed
- Sponsor
- ProKidney
- Start
- Aug 2019
- Primary completion
- Jan 2023
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilparencel in chronic kidney disease (CKD), sponsored by ProKidney. Primary endpoints: Change in estimated Glomerular Filtration Rate and Incidence of renal-specific procedure and/or product related adverse events. Started Aug 2019; status: completed.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04115345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04115345.